Cost-effectiveness of chlamydia vaccination programs for young women

Emerging Infectious Diseases

Volumn 21, Issue 6, 2015, Pages 960-968

  Owusu Edusei, Kwame ^a   Chesson, Harrell W ^a   Gift, Thomas L ^a   Brunham, Robert C ^b   Bolan, Gail ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLAMYDIA VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; IMMUNITY; MALE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; VACCINATION; YOUNG ADULT; CHLAMYDIA INFECTIONS; COST BENEFIT ANALYSIS; HEALTH SURVEY; IMMUNOLOGY; OUTCOME ASSESSMENT; THEORETICAL MODEL; UNITED STATES;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84929392542     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2106.141270     Document Type: Article

References (39)

1. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections, 2008. Geneva: The Organization; 2012.
2. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2012. Atlanta: The Centers; 2013.
3. Satterwhite CL, Torrone E, Meitis E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-93. http://dx.doi.org/10.1097/OLQ.0b013e318286bb53
4. Owusu-Edusei K Jr, Chesson HW, Gift TL, Tao G, Ocfemia MC, Mahajan R, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40:197-201. http://dx.doi.org/10.1097/OLQ.0b013e318285c6d2
5. Stamm WE. Chlamydia trachomatis infections in the adult. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. New York: McGraw Hill; 2008. p. 575-93.
6. Bakken IJ, Skjeldestad FE, Nordbo SA. Chlamydia trachomatis infections increase the risk for ectopic pregnancy: A population-based, nested case-control study. Sex Transm Dis. 2007;34:166-9. http://dx.doi.org/10.1097/01.olq.0000230428.06837.f7
7. Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine. 2014;32:1563-71. http://dx.doi.org/10.1016/j.vaccine.2013.08.020
8. Brunham RC, Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine. 2013;31:1892-7. http://dx.doi.org/10.1016/j.vaccine.2013.01.024
9. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis. 2012;206:1836-43. http://dx.doi.org/10.1093/infdis/jis621
10. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine. 2014;32:1527-35. http://dx.doi.org/10.1016/j.vaccine.2013.07.087
11. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443-50. http://dx.doi.org/10.1016/j.vaccine.2011.07.096
12. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244-51. http://dx.doi.org/10.3201/eid1402.070499
13. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41. http://dx.doi.org/10.3201/eid1301.060438
14. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821-32. http://dx.doi.org/10.1056/NEJMsa0707052
15. Owusu-Edusei K Jr, Gift TL, Chesson HW, Kent CK. Investigating the potential public health benefit of jail-based screening and treatment programs for Chlamydia. Am J Epidemiol. 2013;177:463-73. http://dx.doi.org/10.1093/aje/kws240
16. Gift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis. 2008;35(Suppl):S66-75. http://dx.doi.org/10.1097/OLQ.0b013e31818b64ac
17. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192:1836-44. http://dx.doi.org/10.1086/497341
18. Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol. 2013;178:484-92. http://dx.doi.org/10.1093/aje/kws583
19. Quinn TC, Gaydos C, Shepherd M, Bobo L, Hook EW, Viscidi R, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA. 1996;276:1737-42. http://dx.doi.org/10.1001/jama.1996.03540210045032
20. Garnett GP, Mertz KJ, Finelli L, Levine WC, St. Louis ME. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci. 1999;354:787-97. http://dx.doi.org/10.1098/rstb.1999.0431
21. Van Der Pol B, Liesenfeld O, Williams JA, Taylor SN, Lillis RA, Body BA, et al. Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/GCQ assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2012;50:2244-9. http://dx.doi.org/10.1128/JCM.06481-11
22. Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2007;44(Suppl 3):S77-83. http://dx.doi.org/10.1086/511421
23. Owusu-Edusei K Jr, Nguyen HT, Gift TL. Utilization and cost of diagnostic methods for sexually transmitted infection screening among insured American youth, 2008. Sex Transm Dis. 2013; 40:354-61. http://dx.doi.org/10.1097/OLQ.0b013e318285c58f
24. Owusu-Edusei K, Roby TM, Chesson HW, Gift TL. Productivity costs of nonviral sexually transmissible infections among patients who miss work to seek medical care: evidence from claims data. Sex Health. 2013;10:434-7. http://dx.doi.org/10.1071/SH13021
25. Bureau of Labor Statistics. The editor's desk. Youth employment and unemployment in July 2010, 2013 [cited 2013 Sep 15]. http://www.bls.gov/opub/ted/2010/ted_20100903.htm
26. Blandford JM, Gift TL. Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women. Sex Transm Dis. 2006;33(Suppl):S117-21. http://dx.doi.org/10.1097/01.olq.0000235148.64274.2f
27. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208:385-93. http://dx.doi.org/10.1093/infdis/jit192
28. Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. Washington (DC): National Academy of Sciences; 2000.
29. United States Department of Labor. Consumer price indexes-all urban consumers. 2011 [cited 2013 Dec 15]. http://www.bls.gov/cpi/home.htm
30. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model as an example. International Statistical Review. 1994;62:229-43. http://dx.doi.org/10.2307/1403510
31. Chen MI, Ghani AC, Edmunds WJ. A metapopulation modelling framework for gonorrhoea and other sexually transmitted infections in heterosexual populations. J R Soc Interface. 2009;6:775-91.
32. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165-78. http://dx.doi.org/10.1586/ 14737167.8.2.165
33. Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis. 2009;199:1680-8. http://dx.doi.org/10.1086/598983
34. Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med. 2004;141:501-13. http://dx.doi.org/10.7326/0003-4819-141-7-200410050-00006
35. National Commission for Quality Assurance. Improving quality and patient experience: the state of health care quality. Washington (DC): The Commission; 2013.
36. Heijne JCM, Tao GY, Kent CK, Low N. Uptake of regular Chlamydia testing by US women: a longitudinal study. Am J Prev Med. 2010;39:243-50. http://dx.doi.org/10.1016/j.amepre.2010.05.011
37. Finer LB, Philbin JM. Sexual initiation, contraceptive use, and pregnancy among young adolescents. Pediatrics. 2013;131:886-91. http://dx.doi.org/10.1542/peds.2012-3495
38. Althaus CL, Heijne JC, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics. 2010;2:123-31. http://dx.doi.org/10.1016/ j.epidem.2010.04.002
39. Low N, Heijne JC, Kretzschmar M. Use of mathematical modeling to inform Chlamydia screening policy decisions. J Infect Dis. 2009;199:767-8. http://dx.doi.org/10.1086/596744